FLX925, also known as AMG-925, is a potent and selective type 1 inhibitor of FLT3 that retains its cellular potency against clinically relevant secondary resistance mutations in FLT3 occurring with quizartinib or sorafenib treatment (FLX925 IC50: MOLM13ITD, 15 nM; MOLM13ITD/D835, 28 nM; MV4-11ITD, 16 nM; MV4-11ITD/D835, 19 nM; MV4-11ITD/N841, 16 nM; MV4-11ITD/F691, 73 nM).
FLT3 Inhibitors Related Products:
Crenolanib; Dovitinib; Quizartinib; Brigatinib; Pacritinib; Fedratinib; TG101209; SGI-1776; Tandutinib; SU5614; Tamatinib; G-749